Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 1509  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission

Year : 2009  |  Volume : 1  |  Issue : 1  |  Page : 32-36 Table of Contents     

Synthesis and antimicrobial activity of 2-chloroquinoline incorporated pyrazoline derivatives

1 Department of Pharmaceutical Chemistry, Jamia Hamdard (Hamdard University), New Delhi - 110 062, India
2 Pharmaceutical Biotechnology Laboratory, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi - 110 062, India

Date of Submission14-Nov-2009
Date of Decision28-Nov-2009
Date of Acceptance04-Dec-2009
Date of Web Publication23-Apr-2010

Correspondence Address:
Suresh Kumar
Department of Pharmaceutical Chemistry, Jamia Hamdard (Hamdard University), New Delhi - 110 062
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0975-7406.62684

Rights and Permissions

Purpose : A series of 2-chloroquinoline containing pyrazoline derivatives having 3,4-dichloro/ 3,4-dimethoxy in the phenyl ring were synthesized and screened for their antimicrobial activity against a panel of bacterial and fungal strains. Materials and Methods : The structures of the newly synthesized compounds were established on the basis of spectral data obtained from the FTIR, 1H and 13C-NMR, and mass spectrometry. All the compounds were evaluated for their antibacterial activity against Escherichia coli (NCTC, 10418), Staphylococcus aureus (NCTC, 65710), and Pseudomonas aeruginosa (NCTC, 10662). The compounds were also tested for antifungal activity aganist Aspergillus niger (MTCC, 281), Aspergillus flavus (MTCC, 277), Monascus purpureus (MTCC, 369) and Penicillium citrinum (NCIM, 768) by the cup-plate method. Results : Among the compounds tested, 3,4-dichloro derivatives were comparatively more active in antimicrobial screening with respect to their 3,4-dimethoxy analog. Conclusion : A careful analysis of the antimicrobial activity data of the compounds revealed that compounds 3a, 3b, 3c, and 3e exhibited potent antibacterial

Keywords: Pyrazoline, 2-chloroquinoline, antimicrobial activity

How to cite this article:
Bawa S, Kumar S, Drabu S, Panda BP, Kumar R. Synthesis and antimicrobial activity of 2-chloroquinoline incorporated pyrazoline derivatives. J Pharm Bioall Sci 2009;1:32-6

How to cite this URL:
Bawa S, Kumar S, Drabu S, Panda BP, Kumar R. Synthesis and antimicrobial activity of 2-chloroquinoline incorporated pyrazoline derivatives. J Pharm Bioall Sci [serial online] 2009 [cited 2019 Oct 20];1:32-6. Available from:

The recent literature is enriched with progressive findings about the synthesis and pharmacological activities of pyrazoline and substituted pyrazolines. Pyrazolines have been found to possess antimicrobial, antitubercular, antiamoebic, antidepressant, anticonvulsant, anti-inflammatory, anti-tumor, and antiviral activities, among others. [1],[2],[3],[4],[5],[6],[7],[8],[9] In addition, quinoline derivatives are also known to possess antibacterial, antifungal, anticonvulsant, and antimalarial activities, and the medicinal utility of quinoline as a heterocyclic ring has moved from the antimalarial to almost every branch of medicinal chemistry. [10],[11],[12] Various functional groups, such as, chloro, fluoro, nitro, methoxy, and so on, have an important significance in medicinal chemistry. Especially the dihalogen-like dichloro, as in antifungal azoles, provides a potent antifungal activity for drugs such as Oxiconazole, Ketoconazole, Terconazole, Itraconazole, and so on. [13] Moreover, the 3,4-dichloro function has been regarded as an equivalent to the naphthalene ring as reported for the compound pronethalol, an adrenergic blocker, which was formed by replacing the 3,4-dichlorophenyl group in Dichloroisoproterenol (DCI) with the 2-naphthyl group. [14] Similarly, the 3,4-dimethoxy group has also been associated with potent biological activity. Prompted by these observations it was envisaged to synthesize some new pyrazoline derivatives bearing a 2-chloroquinoline nucleus as well as bifunctional groups, such as, 3,4-dichloro and 3,4-dimethoxy in a single matrix, and also to screen for their antifungal, antibacterial activities.

   Materials and Methods Top

Melting points were determined by the open capillary method using the electrical melting point apparatus and were uncorrected. The IR spectra were recorded as KBr (pallet) on Bio Rad FT-IR spectrophotometer. 1 H and 13 C-NMR spectra were recorded on Bruker DPX 300 MHz spectrophotometer using TMS as the internal standard. The mass spectra were recorded on JEOL SX102/DA-6000 mass spectrometer and elemental analysis was carried out on the Vario-EL III CHNOS-Elemantar analyzer. The lipophilicity of the compounds was calculated using the Chemsketch 12.0 software of the Advanced Chemistry Development (ACD) Laboratory. Thin Layer Chromatography (TLC) was performed to check the purity of the compounds, the spot being located under iodine vapors.

General procedure for the synthesis of chalcones (1a-e, 2a-e)

3,4-Dichloro acetophenone (1) or 3,4-dimethoxy acetophenone (2) (0.01 mol) was added to the mixture of substituted 2-chloroquinoline-3-carboxaldehyde (a-e) (0.01 mol), and aq. sodium hydroxide solution (30%, 1 ml), in ethanol 30 ml. The reaction mixture was stirred overnight at room temperature. Subsequently, this reaction mixture was poured over crushed ice and neutralized to pH 7 with dilute HCl. The yellow solid thus obtained was filtered, washed with water, and dried. The crude product was crystallized with a chloroform-ethanol mixture to afford pure chalcones.

3-(2-chloroquinolin-3-yl)-1-(3,4-dichlorophenyl)prop-2-en-1-one. (1a-e, 2a-e)

IR (KBr) cm -1 ; 1698 (C=O), 1627 (C=N), 1579 (C=C), 747 (C-Cl). 1 H-NMR (300 MHz, DMSO-d 6); δ 7.59-7.64 (m, 2H, Ar-H and CH=CH), 7.73-7.92 (m, 4H, Ar-H and CH=CH), 7.98-8.09 (m, 3H, Ar-H), 8.48 (s, 1H, H-4).

General procedure for the synthesis of Pyrazolines (3a-e, 4a-e)

To a solution of chalcones (1a-e, 2a-e) (0.01 mol) in absolute ethanol (25 ml) containing 1-1.5 ml of acetic acid, an equimolar amount of hydrazine hydrate (0.01 mol) was added and the reaction mixture was refluxed for 12 to 16 hours. After the completion of the reaction, the mixture was concentrated under reduced pressure and then allowed to cool. A solid product separated out, which was filtered, washed with aqueous ethanol, and dried. This product was further purified by crystallization from the ethanol-DMF mixture. The physicochemical data of the synthesized pyrazolines is given in [Table 1]. Spectral data of compounds (3a-e and 4a-e) are given below.

2-chloro-3-[3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]quinoline (3a)

IR (KBr) cm -1 ; 3279 (N-H), 1615 (C=N), 1583 (C=C), 756 (C-Cl). 1 H-NMR (300 MHz, DMSO-d 6); δ 3.19 (dd, 1H, H A , J = 18.09, 4.57 Hz), 3.78 (dd, 1H, H B , J = 17.32, 12.57, Hz), 5.56 (dd, 1H, H X , J = 11.51, 4.33 Hz), 7.08 (d, 1H, Ar-H, J = 6.99 Hz), 7.31 (d, 1H, Ar-H, J = 6.12 Hz), 7.53-7.73 (m, 5H, Ar-H), 7.95 (s, 1H, Ar-H), 11.13 (s, 1H, NH, D 2 O-exchangeble). 13 C-NMR (75 MHz, DMSO-d 6); δ 41.35 (CH 2 ), 60.13 (CH), 112.84, 115.88, 126.43, 128.86, 130.03, 132.47, 133.62, 135.18, 137.41, 141.83, 144.71, 147.91, 149.26, 151.38. DEPT-135; 41.35 (-ve peak, CH 2 ), 60.13 (+ve peak CH). FAB -MS : m/z 377 (M + ), 379 (M+2) [Figure 1].

2-chloro-3-[3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-6-methylquinoline (3b)

IR (KBr) cm -1 ; 3271 (N-H), 1617 (C=N), 1583 (C=C), 751 (C-Cl). 1 H-NMR (300 MHz, DMSO-d 6); δ 2.50 (s, 3H, CH 3 ), 3.20 (dd, 1H, H A , J = 18.12, 4.50 Hz), 3.89 (dd, 1H, H B , J = 18.00, 12.17, Hz), 5.52 (dd, 1H, H X , J = 11.63, 4.28 Hz), 7.20-7.33 (m, 2H, Ar-H), 7.48-7.53 (m, 2H, Ar-H), 7.73-7.80 (m, 2H, Ar-H), 7.97 (s, 1H, Ar-H), 11.86 (s, 1H, NH, D 2 O-exchangeble). 13 C-NMR (75 MHz, DMSO-d 6); δ 21.07 (CH 3 ), 40.87 (CH 2 ), 61.28 (CH), 113.05, 115.93, 126.85, 128.47, 130.14, 131.64, 133.72, 136.23, 137.57, 141.68, 145.71, 147.98, 149.84, 151.37. DEPT-135; 40.87 (-ve peak, CH 2 ), 61.28 (+ve peak CH). FAB -MS : m/z 391 (M + ), 393 (M+2).

2-chloro-3-[3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-7-methylquinoline (3c)

IR (KBr) cm -1 ; 3258 (N-H), 1625 (C=N), 1579 (C=C), 758 (C-Cl). 1 H-NMR (300 MHz, DMSO-d 6); δ 2.51 (s, 3H, CH 3 ), 3.17 (dd, 1H, H A , J = 18.08, 4.77 Hz), 3.75 (dd, 1H, H B , J = 18.07, 12.16, Hz), 5.53 (dd, 1H, H X , J = 11.74, 4.66 Hz), 6.99 (d, 1H, Ar-H, J = 7.90 Hz), 7.10 (s, 1H, Ar-H), 7.49-7.57 (m, 2H, Ar-H), 7.70-7.77 (m, 2H, Ar-H), 7.95 (s, 1H, Ar-H), 11.86 (s, 1H, NH, D 2 O-exchangeble).

2-chloro-3-[3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-8-methylquinoline (3d)

IR (KBr) cm -1 ; 3247 (N-H), 1621 (C=N), 1584 (C=C), 762 (C-Cl). 1 H-NMR (300 MHz, DMSO-d 6); δ 2.76 (s, 3H, CH 3 ), 3.18 (dd, 1H, H A , J = 18.10, 4.52 Hz), 3.76 (dd, 1H, H B , J = 17.89, 12.21 Hz), 5.54 (dd, 1H, H X , J = 11.67, 4.45 Hz), 7.20-7.36 (m, 2H, Ar-H), 7.46-7.54 (m, 2H, Ar-H), 7.69-7.80 (m, 2H, Ar-H), 7.94 (s, 1H, Ar-H), 11.87 (s, 1H, NH, D 2 O-exchangeble).

2-chloro-3-[3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-6-methoxyquinoline (3e)

IR (KBr) cm -1 ; 3263 (N-H), 1622 (C=N), 1583 (C=C), 756 (C-Cl). 1 H-NMR (300 MHz, DMSO-d 6); δ 3.19 (dd, 1H, H A , J = 18.19, 4.53 Hz), 3.75 (dd, 1H, H B , J = 17.93, 12.23, Hz), 3.96 (s, 3H, OCH 3 ), 5.53 (dd, 1H, H X , J = 11.65, 4.21 Hz), 7.29 (d, 1H, Ar-H, J = 7.77 Hz), 7.46-7.54 (m, 3H, Ar-H), 7.69-7.80 (m, 2H, Ar-H), 7.96 (s, 1H, Ar-H), 11.82 (s, 1H, NH, D 2 O-exchangeble).

2-chloro-3-[3-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]quinoline (4a)

IR (KBr) cm -1 ; 3279 (N-H), 1615 (C=N), 1583 (C=C), 756 (C-Cl). 1 H-NMR (300 MHz, DMSO-d 6); δ 3.21 (dd, 1H, H A , J = 18.31, 4.50 Hz), 3.80 (s, 6H, OCH 3 ), 3.99 (dd, 1H, H B , J = 16.82, 12.22, Hz), 5.87 (dd, 1H, H X , J = 11.72, 4.23 Hz), 7.04-7.10 (m, 3H, Ar-H), 7.64-7.66 (m, 2H, Ar-H), 7.80 (t, 1H, Ar-H, J = 7.68), 7.95-7.98 (m, 2H, Ar-H), 11.19 (s, 1H, NH, D 2 O-exchangeble).

2-chloro-3-[3-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-6-methylquinoline (4b)

IR (KBr) cm -1 ; 3273 (N-H), 1620 (C=N), 1587 (C=C), 756 (C-Cl). 1 H-NMR (300 MHz, DMSO-d 6); δ 2.51 (s, 3H, CH 3 ), 3.16 (dd, 1H, H A , J = 18.13, 4.60 Hz), 3.77 (s, 6H, 2xOCH 3 ), 3.94 (dd, 1H, H B , J = 18.01, 12.11, Hz), 5.57 (dd, 1H, H X , J = 11.89, 4.59 Hz), 7.03-7.10 (m, 3H, Ar-H), 7.49-7.57 (m, 2H, Ar-H), 7.70-7.73 (m, 1H, Ar-H), 7.95 (s, 1H, Ar-H), 11.86 (s, 1H, NH, D 2 O-exchangeble).

2-chloro-3-[3-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-7-methylquinoline (4c)

IR (KBr) cm -1 ; 3326 (N-H), 1626 (C=N), 1581 (C=C), 748 (C-Cl). 1 H-NMR (300 MHz, DMSO-d 6); δ 2.52 (s, 3H, CH 3 ), 3.18 (dd, 1H, H A , J = 18.07, 4.57 Hz), 3.76 (s, 6H, 2xOCH 3 ), 3.93 (dd, 1H, H B , J = 18.14, 12.23, Hz), 5.58 (dd, 1H, H X , J = 11.76, 4.63 Hz), 7.07-7.12 (m, 3H, Ar-H), 7.39-7.43 (m, 2H, Ar-H), 7.73 (d, 1H, Ar-H, J = 7.68 Hz), 7.98 (s, 1H, Ar-H), 11.53 (s, 1H, NH, D 2 O-exchangeble).

2-chloro-3-[3-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-8-methylquinoline (4d)

IR (KBr) cm -1 ; 3267 (N-H), 1630 (C=N), 1574 (C=C), 752 (C-Cl). 1 H-NMR (300 MHz, DMSO-d 6); δ 2.71 (s, 3H, CH 3 ), 3.16 (dd, 1H, H A , J = 18.06, 4.63 Hz), 3.73 (s, 6H, 2xOCH 3 ), 3.91 (dd, 1H, H B , J = 18.08, 12.17 Hz), 5.57 (dd, 1H, H X , J = 11.59, 4.61 Hz), 7.03-7.08 (m, 3H, Ar-H), 7.47-7.52 (m, 2H, Ar-H), 7.82 (d, 1H, Ar-H, J = 7.72 Hz), 8.03 (s, 1H, Ar-H), 11.49 (s, 1H, NH, D 2 O-exchangeble).

2-chloro-3-[3-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-6-methoxyquinoline (4e)

IR (KBr) cm -1 ; 3283 (N-H), 1634 (C=N), 1582 (C=C), 760 (C-Cl). 1 H-NMR (300 MHz, DMSO-d 6); δ 3.17 (dd, 1H, H A , J = 18.13, 4.69 Hz), 3.76 (s, 6H, 2xOCH 3 ), 3.86-3.96 (m, 4H, H B and OCH 3 ), 5.54 (dd, 1H, H X , J = 11.65, 4.71 Hz), 7.04-7.09 (m, 3H, Ar-H), 7.19 (s, 1H, Ar-H), 7.50 (d, 1H, Ar-H, J = 8.09 Hz), 7.89-7.95 (m, 2H, Ar-H), 8.02 (s, 1H, Ar-H), 11.73 (s, 1H, NH, D 2 O-exchangeble).

Antimicrobial activity

The newly synthesized compounds were tested for their growth inhibitory effect against bacterial strains,  Escherichia More Details coli NCTC 10418, Staphylococcus aureus NCTC 65710, and Pseudomonas aeruginosa NCTC 10662, and also against fungal strains Aspergillus niger MTCC 281, Aspergillus flavus MTCC 277, Monascus purpureus MTCC 369, and Penicillium citrinum NCIM 768, by using the cup plate method. [15],[16] Nutrient agar and potato dextrose agar were used as culture mediums for the antibacterial and antifungal activity, respectively. Using an agar punch, wells were made on these seeded agar plates and dilution of 200 μg/ml of test compounds, in DMSO, were added into each well, labeled previously. A control was also prepared using the DMSO solvent. The petri plate were prepared in triplicate and maintained at 30 for 72 hours for fungi and at 37C for 24 hours for bacteria. Antimicrobial activity was determined by measuring the zone of inhibition and results have been reported in [Table 2] as the mean zone of inhibition in Millimeter Standard Deviation. Fluconazole and Ciprofloxacin at concentrations of 200 g/ml were used as reference drugs for the antifungal and antibacterial activities, respectively.

   Results and Discussion Top


The synthesis of the new derivatives of pyrazoline were carried out as outlined in scheme 1. The chalcones were prepared by reacting 3,4-dichloro/3,4-dimethoxy acetophenone (1,2), with the appropriately substituted 2-chloro-3-formylquinoline (a-e), in the presence of base NaOH, by the conventional Claisen-Schmidt condensation. For this purpose the required substituted 2-chloro-3-formyl-quinoline was prepared from the substituted N-aryl acetamide by the action of DMF / POCl 3 using Meth-Cohn and Narine procedures. [17] The reaction of 3-(2-chloro-substituted-quinolin-3-yl)-1-(3,4-dichlorophenyl)prop-2-en-1-one (1a-e) and 3-(2-chloro-substituted-quinolin-3-yl)-1-(3,4 dimethoxyphenyl) prop-2-en-1-one (2a-e) with hydrazine hydrate was carried out by refluxing it in absolute ethanol in the presence of glacial acetic acid, which gave 2-chloro-3-[3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-substituted-quinoline (3a-e) and 2-chloro-3-[3-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-substituted-quinoline (4a-e). The reaction time varied from 12 to 16 hours, and an yield ranging from 45 to 67% was obtained. The physicochemical data of pyrazolines have been mentioned in [Table 1].

The 1 H-NMR spectra of pyrazolines (3a-e, 4a-e) displayed three characteristic signals due to the diastereotopic proton [18],[19] (H A , H B and H X ). The H A proton, was cis to H X resonated upfield in the range δ 3.16 - 3.21 as doublet of doublet (dd, J = ~ 18.07 and 4.60 Hz), while the H B proton was trans to H X resonated downfield in the range of 3.75 - 3.99 (dd, J =17.89 and 12.21 Hz). The H X proton which was vicinal to two methylene protons (H A and H B ) was also observed as doublet of doublet at d values ranging from 5.52 to 5.87 (dd, J = 11.74 and 4.66 Hz).

The cyclization of chalcone into pyrazolines was further supported by the 13 C-NMR of two prototype compounds 3a and 3b, in which the C-4 and C-5 carbon resonated at d 41.35 and 60.13 and 40.87 and 61.28, respectively. These values are in close agreement with the reported values for pyrazolines carbon C-4 and C-5. [19],[20] DEPT-135 is an important tool of 13 C-NMR spectroscopy in which only the primary, secondary, and tertiary carbons, which have an attached proton, give a signal, but the phases of the signals are different, depending on whether the number of the attached hydrogen is an odd or even number. Signals arising from the CH or CH 3 group will give positive peaks, while signals arising from the CH 2 group will give negative (inverse) peaks. [21] DEPT-135 spectra of two compounds 3a and 3b revealed positive peaks at d 60.13 and 61.28, due to the CH of pyrazoline, that is, (C-5), and negative (inverse) peaks at 41.35 and 40.87, due to CH 2 of pyrazoline (C-4), respectively. The combination of 1 H-NMR, 13 C-NMR, and DEPT-135, provides a strong evidence in support of structures assigned to pyrazoline derivatives.

The FAB-MS spectra of two selected compounds, that is, 3a and 3b showed molecular ion peaks at m/z 377 and m/z 391. The (M+2) appeared at peaks m/z 379 and 393, respectively. These data were found to be satisfactory for the structures assigned to compounds (3a-e, 4a-e).

Antimicrobial activity

The newly synthesized compounds were screened for their antibacterial and antifungal activities against organisms  Escherichia coli Scientific Name Search  10418, Staphylococus aureus NCTC 6571,  Pseudomonas aeruginosa Scientific Name Search i>NCTC 10662, Aspergillus niger MTCC 281, Aspergillus flavus MTCC 277, Monascus purpureus MTCC 369, and Penicillium citrinum NCIM 768, in DMSO, by the cup plate method. On the basis of the observed zone of inhibition values, it appears that there are significant differences in the antibacterial and antifungal potentials of prepared quinolinyl pyrazolines. Although the difference among the responses of different compounds was not significant, with regard to the antimicrobial activity of pyrazolines, these compounds were comparatively more active against the bacterial and fungal strains. Pyrazoline derivatives showed 6.83 - 12.16 mm zone of inhibition against the fungal strains and compounds 3a, 3b, 3c, 3d, and 3e, exhibited the highest antifungal activity against Aspergillus niger MTCC 281 (10.58 - 12.16 mm). The pyrazoline derivatives exhibited very good antibacterial activity against the test organism (8.24 - 14.07 mm). Compounds 3a, 3b, 3c, and 3e exhibited potent antibacterial activity. A careful analysis of the antimicrobial activity data of the compounds [Table 2] suggested that 3,4-dichloro derivatives were comparatively more active in antimicrobial screening, with respect to their 3,4-dimethoxy analog, which may be attributed to the high C log P values.

   Acknowledgments Top

The authors are thankful to the Department of Pharmaceutical Chemistry, Faculty of the Pharmacy, and Jamia Hamdard for providing the necessary facility, and also CDRI, Lucknow, India for recording the FAB-MS spectral data.

   References Top

1.Zampieri D, Mamolo MG, Laurini E, Scialino G, Banfi E, Vio L. Antifungal and antimy-cobacterial activity of 1-(3, 5-diaryl-4,5-dihydro-1H-pyrazol-4-yl)-1H-imidazole derivatives. Bioorg Med Chem 2008;16:4516-22.  Back to cited text no. 1      
2.Shaharyar M, Siddiqui AA, Ali MA, Sriram D, Yogeeswari P. Synthesis and in vitro an-timycobacterial activity of N1-nicotinoyl-3-(4Ͳ-hydroxy-3Ͳ-methyl phenyl)-5-[(sub)phenyl]-2-pyrazolines. Bioorg Med Chem Lett 2006;16:3947-9.  Back to cited text no. 2      
3.Abid M, Azam A. Synthesis and antiamoebic activities of 1-N-substituted cyclised pyrazoline analogues of thiosemicarbazones. Bioorg Med Chem 2005;13:2213-20.  Back to cited text no. 3      
4.Reddy MV, Billa VK, Pallela VR, Mallireddigari MR, Boominathan R, Gabriel JL, et al. Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors. Bioorg Med Chem 2008;16:3907-3916.  Back to cited text no. 4      
5.Johnson M, Younglove B, Lee L, LeBlanc R, Holt H Jr, Hills P, et al. Design, synthesis, and biological testing of pyrazoline derivatives of combretastatin-A4. Bioorg Med Chem Lett 2007;17:5897-901.  Back to cited text no. 5      
6.Ozdemir Z, Kandilci HB, GόmόΊel B, CaliΊ U, Bilgin AA. Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)- pyrazoline derivatives. Eur J Med Chem 2007;42:373-9.  Back to cited text no. 6      
7.Zhang X, Li X, Allan GF, Sbriscia T, Linton O, Lundeen SG, et al. Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators. J Med Chem 2007;50:3857-69.  Back to cited text no. 7      
8.Carriσn MD, Lσpez Cara LC, Camacho ME, Tapias V, Escames G, Acuρa-Castroviejo D, et al. Pyrazoles and pyrazolines as neural and inducible nitric oxide synthase (nNOS and iNOS) potential inhibitors (III). Eur J Med Chem 2008;43:2579-91.   Back to cited text no. 8      
9.Shahar YM, Bakht MA, Siddiqui AA, Abdullah MM, De Clercq E. Synthesis and evaluation of in vitro antiviral activity of novel phenoxy acetic acid derivatives. J Enzyme Inhib Med Chem 2009;24:876-82.  Back to cited text no. 9      
10.Reddy GV, Kanth SR, Maitraie D, Narsaiah B, Rao PS, Kishore KH, et al. Design, synthesis, structure-activity relationship and antibacterial activity series of novel imidazo fused quinolone carboxamides. Eur J Med Chem 2009;44:1570-8.   Back to cited text no. 10      
11.Li-Ping G, Qing-Hao J, Guan-Rong T, Kyu-Yun C, Zhe-Shan Q. Synthesis of some quinoline-2(1H)-one and 1, 2, 4 - triazolo[ 4 , 3 -a] quinoline derivatives as potent anticonvulsants. J Pharm Pharmaceut Sci 2007;10:254-62.  Back to cited text no. 11      
12.Melιndez Gσmez CM, Kouznetsov VV, Sortino MA, Alvarez SL, Zacchino SA. In vitro antifungal activity of polyfunctionalized 2-(hetero)arylquinolines prepared through imino Diels-Alder reactions. Bioorg Med Chem 2008;16:7908-20.   Back to cited text no. 12      
13.Martin AR. Anti-infective Agents. In: Delgado JN, Remers WA, editors. Wilson and Gi vold's Text Book of Organic Medicinal and Pharmaceutical Chemistry. 10th ed.Philadelphia : Lippincott Williams and Wilkins; 1998. p. 173-221.  Back to cited text no. 13      
14.Hernαndez-Campos A, Ibarra-Velarde F, Vera-Montenegro Y, Rivera-Fernαndez N, Castillo R. Synthesis and fasciolicidal activity of 5-chloro-2-methylthio-6-(1-naphthyloxy)-1H-benzimidazole. Chem Pharm Bull (Tokyo) 2002;50:649-52.  Back to cited text no. 14      
15.Barry AL. The antimicrobial susceptibility test: Principle and practice. Philadelphia: Illus Lea and Febiger: 1976. p. 180, Biol Abstr, 64, 1977, 25183.  Back to cited text no. 15      
16.Cruickshank R, Duguid JP, Marion BP, Swain RH. Medical microbiology. 12th ed.Vol-2. Churchill Livingstone; London: 1975.  Back to cited text no. 16      
17.Meth-Cohn O, Narine B, Tarnowski B. The synthesis of 2-chloroquinoline-3-carboxaldehyde. J Chem Soc Perkin 1981;1:1520-30.  Back to cited text no. 17      
18.Amir M, Kumar S. Synthesis and anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation activities of 3,5-dimethyl pyrazoles, 3-methyl pyrazol-5-ones and 3,5-disubstituted pyrazolines. Indian J Chem Br 2005;44:2532-7.  Back to cited text no. 18      
19.Aggarwal R, Kumar V, Singh SP. Synthesis of some new1-(6-fluorobenzothiazol-2-yl) -3-(4-fluoro-phenyl) -5-arylpyrazolines and their iodine (III) mediated oxidation to corres-ponding pyrazoles. Indian J Chem Br 2007;46:1332-6.   Back to cited text no. 19      
20.Ozdemir A, Turan-Zitouni G, Kaplancikh ZA, Revial G, Guven K. Synthesis and antimicrobial activity of 1-(4-aryl-2-thiazolyl)-5-aryl-2-pyrazoline derivatives. Eur J Med Chem 2008;42:403-409.   Back to cited text no. 20      
21.Pavia DL, Lampman GM, Kriz GS. Introduction to spectroscopy. 3rd ed. Singapore: Thomson Asia Pvt Ltd; 2006. p. 532.  Back to cited text no. 21      


  [Figure 1]

  [Table 1], [Table 2]

This article has been cited by
1 Synthesis and In-vitro Antimicrobial Activity of Secondary and Tertiary Amines Containing 2-Chloro-6-methylquinoline Moiety
Suresh Kumar,Sandhya Bawa,Darpan Kaushik,Bibhu P. Panda
Archiv der Pharmazie. 2011; 344(7): 474
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Materials and Me...
    Results and Disc...
    Article Figures
    Article Tables

 Article Access Statistics
    PDF Downloaded564    
    Comments [Add]    
    Cited by others 1    

Recommend this journal